Search →

Overview

Investing In a Better Future

If you’ve come to this page, we hope you are as excited about Bicycle as we are. Our goal is to be one of the world’s leading solid tumor therapeutics companies. Please give us a call or send us an email if you have questions about our science, clinical programs, strategy or any other aspect of the Bicycle story.

Presentation

10/31/24
October 2024 Corporate Deck
Press
Date
Title
Date
12/12/24
Title
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Date
12/10/24
Title
Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts
Date
12/02/24
Title
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
11/25/24
Title
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources →

Search